Mesa Laboratories
MLAB
126.64
-3.33
-2.56%
Mesa Laboratories
US · MLAB
#3485 by market cap
126.64
-3.33
-2.56%
Live - 5344 symbols - heartbeat 126s ago
· 2026-10-08 10:09
Pre-market
129.59
-0.28%
After-hours
130.00
+0.03%
- Market cap
- 708.63M
- P/E (TTM)i
- 148.98
- P/Bi
- 3.75
- EPSi
- 1.21
- Div yieldi
- 0.51%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on MLAB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.00, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3.38% YoY
Margins
- Gross margin
- 63.53%
- Operating margin
- 7.43%
- Net margin
- 2.69%
Key ratios & quality
- Enterprise valuei
- 836.87M
- PEG ratioi
- 1.60
- Altman Z-Scorei
- 2.00
PEG uses trailing P/E against the 3-year net income growth rate (93.25%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 103.14M | 117.69M | 133.94M | 184.34M | 219.08M | 216.19M | 240.98M | 249.13M |
| Gross profit | 60.92M | 65.36M | 87.01M | 109.09M | 133.69M | 133.25M | 150.87M | 158.27M |
| Selling & admin expenses | 39.56M | 51.08M | 64.27M | 88.62M | 109.88M | 111.49M | 115.02M | 119.45M |
| Research & development | 3.51M | 6.36M | 10.39M | 15.77M | 20.49M | 19.30M | 19.52M | 20.31M |
| Operating profit | 17.86M | 7.92M | 12.36M | 4.70M | 3.32M | 2.46M | 16.34M | 18.51M |
| Pretax profit | 8.62M | 3.86M | 2.30M | 3.57M | -389.00K | -275.65M | 5.96M | 12.01M |
| Tax | 1.14M | 2.08M | -971.00K | 1.70M | -1.32M | -21.40M | 7.94M | 5.30M |
| Net profit | 7.48M | 1.78M | 3.27M | 1.87M | 930.00K | -254.25M | -1.97M | 6.71M |
| Basic EPS | 2 | 0 | 1 | 0 | 0 | -47 | 0 | 1 |
| Diluted EPS | 1.86 | 0.41 | 0.64 | 0.35 | 0.17 | -47.20 | -0.36 | 1.21 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 62.14M | 59.54M | 60.74M | 65.13M | 63.72M | 60.14M |
| Gross profit | 38.41M | 36.94M | 37.33M | 41.80M | 42.21M | 39.01M |
| Selling & admin expenses | 31.85M | 28.89M | 27.56M | 28.79M | 34.21M | 27.26M |
| Research & development | 5.10M | 4.98M | 5.05M | 5.03M | 5.25M | 4.73M |
| Operating profit | 1.47M | 3.06M | 4.72M | 7.98M | 2.75M | 7.03M |
| Pretax profit | 461.00K | 7.01M | 2.00M | 4.60M | -1.59M | 4.35M |
| Tax | 7.58M | 2.27M | -477.00K | 966.00K | 2.54M | 1.52M |
| Net profit | -7.11M | 4.74M | 2.48M | 3.63M | -4.14M | 2.83M |
| Basic EPS | -1 | 1 | 0 | 1 | -1 | 1 |
| Diluted EPS | -1.31 | 0.85 | 0.45 | 0.65 | -0.75 | 0.49 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 33.62M | 122.79M | 303.75M | 124.32M | 118.98M | 109.35M | 102.69M | 106.27M |
| Cash & ST investments | 10.19M | 81.38M | 263.87M | 49.35M | 32.91M | 28.21M | 27.32M | 26.93M |
| Inventory | 6.77M | 14.23M | 11.18M | 24.61M | 34.64M | 32.68M | 25.37M | 26.37M |
| Total assets | 156.77M | 409.11M | 601.48M | 707.37M | 661.83M | 446.80M | 433.35M | 427.75M |
| Total current liabilities | 23.66M | 26.01M | 32.58M | 48.06M | 43.36M | 44.31M | 163.96M | 61.90M |
| Short-term debt | 2.13M | 1.10M | 1.02M | 2.77M | 2.87M | 2.99M | 104.57M | 9.31M |
| Long-term debt | 20.61M | 140.28M | 145.68M | 218.37M | 183.27M | 221.70M | 76.90M | 145.86M |
| Total liabilities | 45,456,000.00 | 189,095,000.00 | 195,248,000.00 | 313,568,000.00 | 268,352,000.00 | 301,403,000.00 | 273,518,000.00 | 241,502,000.00 |
| Total equity | 111.31M | 220.01M | 406.23M | 393.80M | 393.48M | 145.39M | 159.83M | 186.25M |
| Retained earnings | 73.30M | 72.36M | 72.46M | 76.68M | 74.20M | -183.49M | -188.94M | -185.75M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 102.69M | 98.26M | 97.43M | 105.63M | 106.27M | 102.85M |
| Cash & ST investments | 27.32M | 21.28M | 20.42M | 28.98M | 26.93M | 30.70M |
| Inventory | 25.37M | 28.11M | 27.74M | 26.56M | 26.37M | 27.23M |
| Total assets | 433.35M | 435.74M | 430.35M | 434.85M | 427.75M | 419.22M |
| Total current liabilities | 163.96M | 149.49M | 48.30M | 54.40M | 61.90M | 57.32M |
| Short-term debt | 104.57M | 105.40M | 8.50M | 9.05M | 9.31M | 8.26M |
| Long-term debt | 76.90M | 79.53M | 170.16M | 160.97M | 145.86M | 137.24M |
| Total liabilities | 273,518,000.00 | 263,247,000.00 | 251,883,000.00 | 248,158,000.00 | 241,502,000.00 | 230,464,000.00 |
| Total equity | 159.83M | 172.50M | 178.47M | 186.69M | 186.25M | 188.76M |
| Retained earnings | -188.94M | -185.07M | -183.47M | -180.73M | -185.75M | -183.80M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 30.55M | 26.99M | 37.07M | 39.22M | 27.98M | 44.13M | 46.81M | 42.83M |
| Depreciation & amortization | 9.43M | 12.99M | 17.66M | 25.07M | 33.13M | 31.57M | 24.53M | 23.27M |
| Free cash flow | 29.29M | 25.49M | 35.08M | 34.79M | 23.44M | 41.57M | 42.31M | 39.58M |
| Dividends paid | -2.46M | -2.72M | -3.17M | -3.34M | -3.41M | -3.45M | -3.47M | -3.52M |
| Stock buybacks / issuance | 0 | 85.00M | 145.94M | -- | -- | -- | -- | -- |
| Ending cash balance | 10.19M | 81.38M | 263.87M | 49.35M | 32.91M | 28.21M | 27.32M | 26.93M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 12.67M | 1.89M | 8.22M | 18.75M | 13.96M | 14.74M |
| Depreciation & amortization | 7.50M | 5.96M | 5.85M | 5.72M | 5.75M | 5.65M |
| Free cash flow | 11.66M | 884.00K | 7.13M | 18.02M | 13.55M | 14.18M |
| Dividends paid | -870.00K | -873.00K | -882.00K | -884.00K | -884.00K | -884.00K |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 27.32M | 21.28M | 20.42M | 28.98M | 26.93M | 30.70M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 7.10 | 0.81 | 1.05 | 0.47 | 0.24 | -94.36 | -1.29 | 3.88 |
| ROA %i | 4.66 | 0.47 | 0.64 | 0.29 | 0.14 | -45.87 | -0.45 | 1.56 |
| ROIC %i | 5.35 | 1.88 | 1.98 | 0.81 | 0.75 | -52.44 | 1.93 | 3.85 |
| 5-year avg ROE %i | 8.88 | 6.31 | 3.70 | 1.34 | 1.99 | -18.31 | -18.78 | -18.21 |
| EBIT margin %i | 17.31 | 7.59 | 7.71 | 4.05 | 2.00 | -124.87 | 7.39 | 9.11 |
| FCF / sales %i | 28.40 | 21.29 | 26.19 | 18.87 | 10.70 | 19.23 | 17.56 | 15.89 |
| Current ratioi | 1.42 | 4.72 | 9.32 | 2.59 | 2.74 | 2.47 | 0.63 | 1.72 |
| Quick ratioi | 0.96 | 3.94 | 8.83 | 1.88 | 1.74 | 1.52 | 0.42 | 1.15 |
| Debt / assetsi | 14.50 | 34.56 | 24.39 | 31.26 | 28.13 | 50.29 | 41.88 | 36.28 |
| LT debt / equityi | 18.52 | 63.76 | 35.86 | 55.45 | 46.58 | 152.48 | 48.11 | 78.31 |
| Interest coveragei | -- | 1.62 | 1.29 | 1.92 | 0.92 | -47.38 | 1.50 | 2.12 |
| Revenue CAGR (3Y) %i | 6.80 | 7.91 | 11.67 | 21.36 | 23.02 | 17.30 | 9.34 | 4.38 |
| Net income CAGR (3Y) %i | -12.49 | -45.83 | -- | -37.00 | -19.43 | -- | -- | 93.25 |
| FCF CAGR (3Y) %i | 47.25 | 64.76 | 15.24 | 5.90 | -2.76 | 5.82 | 6.74 | 19.08 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -1.29 | -0.38 | -0.92 | 2.18 | 3.88 | 2.66 |
| ROA %i | -0.45 | -0.14 | -0.36 | 0.86 | 1.56 | 1.12 |
| ROIC %i | 1.93 | 2.08 | 1.77 | 3.17 | 3.85 | 3.21 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.39 | 8.37 | 7.47 | 9.97 | 9.11 | 8.09 |
| FCF / sales %i | 17.56 | 13.76 | 15.08 | 15.23 | 15.89 | 21.17 |
| Current ratioi | 0.63 | 0.66 | 2.02 | 1.94 | 1.72 | 1.79 |
| Quick ratioi | 0.42 | 0.40 | 1.25 | 1.27 | 1.15 | 1.14 |
| Debt / assetsi | 41.88 | 45.35 | 44.25 | 41.62 | 36.28 | 34.71 |
| LT debt / equityi | 48.11 | 53.44 | 101.94 | 92.09 | 78.31 | 72.71 |
| Interest coveragei | 1.50 | 1.81 | 1.66 | 2.33 | 2.12 | 1.86 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Sterilization and Disinfection Control is the largest reported line at 40.75% of revenue, across 4 reported segments.
- No single line clears half of revenue; Calibration Solutions is next at 22.09%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Sterilization and Disinfection Control40.75%
Calibration Solutions22.09%
Biopharmaceutical Development20.05%
Clinical Genomics17.11%
Quote time 2026-10-08 10:09:46 · For reference only, not investment advice and not tailored to your situation.